Epitranscriptomics of cancer

doi:10.5306/wjco.v9.i3.42

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 3

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (14375)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

777

WORD

342

HTML

7041

Figures (1-2)

629

Tables (1-1)

689

Sum=9478

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

914

Download

1335

Sum=2249

Publishing Process of This Article

Item

Count

Browse

1042

Download

1609

Sum=2651

Jun 10, 2018 (publication date) through Mar 5, 2026

Times Cited of This Article

Times Cited (25)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Review

World J Clin Oncol. Jun 10, 2018; 9(3): 42-55
Published online Jun 10, 2018. doi: 10.5306/wjco.v9.i3.42

Epitranscriptomics of cancer

Marina Tusup, Thomas Kundig, Steve Pascolo

Marina Tusup, Thomas Kundig, Steve Pascolo, Department of Dermatology, University Hospital of Zürich, Zurich 8091, Switzerland

Marina Tusup, Thomas Kundig, Steve Pascolo, Faculty of Medicine, University of Zurich, Zurich 8091, Switzerland

Author contributions: All three authors contributed to writing this review.

Supported by University of Zurich: “URPP: Translational Cancer research”; and the “MERIT” project supported by the FP7 European Union’s Research and Innovation Funding program.

Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.

Correspondence to: Steve Pascolo, PhD, Senior Scientist, Department of Dermatology, University Hospital of Zürich, Gloriastrasse 31, Zurich 8091, Switzerland. steve.pascolo@usz.ch

Telephone: +41-44-6342877 Fax: +41-44 6342872

Received: February 7, 2018
Peer-review started: February 7, 2018
First decision: March 7, 2018
Revised: April 18, 2018
Accepted: May 23, 2018
Article in press: May 23, 2018
Published online: June 10, 2018
Processing time: 119 Days and 12.2 Hours

Abstract

The functional impact of modifications of cellular RNAs, including mRNAs, miRNAs and lncRNAs, is a field of intense study. The role of such modifications in cancer has started to be elucidated. Diverse and sometimes opposite effects of RNA modifications have been reported. Some RNA modifications promote, while others decrease the growth and invasiveness of cancer. The present manuscript reviews the current knowledge on the potential impacts of N6-Methyladenosine, Pseudouridine, Inosine, 2’O-methylation or methylcytidine in cancer’s RNA. It also highlights the remaining questions and provides hints on research avenues and potential therapeutic applications, whereby modulating dynamic RNA modifications may be a new method to treat cancer.

Keywords: RNA modifications; N6-methyladenosine; 5-methylcytidine; 2’O-methylation or methylcytidine; Pseudouridine; Inosine

Core tip: The present manuscript reviews the current knowledge on RNA modifications in cancer. The potential impacts of N6-Methyladenosine, Pseudouridine, Inosine, 2’O-methylation or methylcytidine in cancer’s RNA is presented and discussed. The review also highlights the remaining questions and provides hints on research avenues and potential therapeutic applications, whereby modulating dynamic RNA modifications may be a new method to treat cancer.